Maridebart Cafraglutide for Obesity
(MARITIME-2 Trial)
Recruiting at 30 trial locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Recruiting
Sponsor: Amgen
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Research Team
M
MD
Principal Investigator
Amgen
Eligibility Criteria
Adults with Type 2 Diabetes Mellitus (T2DM) who are overweight or have obesity can join this trial. They should be at least 18 years old, have a BMI of 27 kg/m^2 or higher, and have tried losing weight unsuccessfully through diet and exercise.Inclusion Criteria
My BMI is 27 or higher.
I have tried and failed to lose weight through diet and exercise.
I have been diagnosed with type 2 diabetes.
See 1 more
Treatment Details
Interventions
- Maridebart Cafraglutide (GLP-1 Receptor Agonist)
Trial OverviewThe trial is testing the effectiveness of Maridebart cafraglutide compared to a placebo in reducing body weight percentage among adults with T2DM who are also overweight or obese.
Participant Groups
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Maridebart Cafraglutide Medium DoseExperimental Treatment1 Intervention
Participants will receive maridebart cafraglutide medium dose SC for 72 weeks.
Group II: Maridebart Cafraglutide Low DoseExperimental Treatment1 Intervention
Participants will receive maridebart cafraglutide low dose SC for 72 weeks.
Group III: Maridebart Cafraglutide High DoseExperimental Treatment1 Intervention
Participants will receive maridebart cafraglutide high dose subcutaneously (SC) for 72 weeks.
Group IV: PlaceboPlacebo Group1 Intervention
Participants will receive placebo SC for 72 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Amgen
Lead Sponsor
Trials
1,508
Recruited
1,433,000+
Founded
1980
Headquarters
Thousand Oaks, USA
Known For
Human Therapeutics
Top Products
Enbrel, Prolia, Neulasta, Otezla
Robert A. Bradway
Amgen
Chief Executive Officer since 2012
MBA from Harvard Business School
Paul Burton
Amgen
Chief Medical Officer since 2023
MD from University of London, PhD in Molecular and Cellular Biology from Imperial College London